Vaccine and Immunotherapy Center, Infectious Diseases Medicine, Massachusetts General Hospital, Charlestown, MA, USA.
Hum Vaccin Immunother. 2012 Jul;8(7):1010-2. doi: 10.4161/hv.20805. Epub 2012 Jul 1.
Emerging and re-emerging infectious diseases represent a major challenge to vaccine development since it involves two seemingly contradictory requirements. Rapid and flexible vaccine generation while using technologies and processes that can facilitate accelerated regulatory review. Development in the "-omics" in combination with advances in vaccinology offer novel opportunities to meet these requirements. Here we describe how a consortium of five different organizations from academia and industry is addressing these challenges. This novel approach has the potential to become the new standard in vaccine development allowing timely deployment to avert potential pandemics.
新发和再现传染病对疫苗开发构成了重大挑战，因为这涉及到两个看似矛盾的要求。一方面需要快速灵活地生成疫苗，另一方面又要使用能够促进加速监管审查的技术和流程。“组学”的发展与疫苗学的进步相结合，为满足这些要求提供了新的机会。在这里，我们描述了来自学术界和工业界的五个不同组织的联盟如何应对这些挑战。这种新方法有可能成为疫苗开发的新标准，从而能够及时部署以避免潜在的大流行。
